Short-course, intensity-modulated radiotherapy for localized prostate cancer

Cancer Journal

Volumn 7, Issue 5, 2001, Pages 421-426

  Kupelian, Patrick A ^a,b   Willoughby, Twyla R ^a,b  

^a Cleveland Clinic Foundation ^*

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Intensity modulation; Local therapy; Prostatic neoplasms; Radiotherapy; Toxicity

Indexed keywords

ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DYNAMICS; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROTOXICITY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM DISEASE; TOXICITY; ULTRASOUND; ADENOCARCINOMA; BLADDER; COMPUTER ASSISTED RADIOTHERAPY; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RECTUM;

ADENOCARCINOMA; DOSE FRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY, CONFORMAL; RECTUM; URINARY BLADDER;

EID: 0035461203     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Hanks GE, Hanlon AL, Pinover WH et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 2000;46:823-832.
2. Hanks GE, Hanlon AL, Pinover WH et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy [see comments]. Cancer J Sci Am 1999; 5:152-158.
3. Kupelian PA. Improvement in overall survival for patients with localized prostate cancer with higher than standard radiation doses: preliminary results. J Urol 1999;161:386.
4. Kupelian PA, Mohan DS, Lyons J et al. Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 2000;46:567-574.
5. Lyons JA, Kupelian PA, Mohan DS et al. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 2000;55:85-90.
6. Pollack A, Zagars GK. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys 1997;39:1011-1018.
7. Pollack A, Zagars GK, Smith LG et al. Preliminary results of a randomized dose-escalation study comparing 70 Gy to 78 Gy for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1999;45:146.
8. Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
9. Zelefsky MJ, Fuks Z, Wolfe T et al. Locally advanced prostatic cancer: long-term toxicity outcome after three-dimensional conformal radiation therapy: a dose-escalation study. Radiology 1998; 209:169-174.
10. Zelefsky MJ, Leibel SA, Kutcher GJ et al. Three-dimensional conformal radiotherapy and dose escalation: where do we stand? Semin Radiat Oncol 1998;8:107-114.
11. Mohan DS, Kupelian PA, Willoughby TR. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. Int J Radiat Oncol Biol Phys 2000;46:575-580.
12. Katcher J, Kupelian PA, Zippe C et al. Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys 1997;37:871-876.
13. Willoughby TR, Mohan D, Weinhous M et al. Improvement in localization of prostate using a transabdominal ultrasound based system as assessed by implanted fiducial markers. Radiology 1999; 213:110.
14. Lattanzi J, McNeely S, Das I et al. A comparison of daily CT localization to a daily ultrasound based system (BAT) in prostate carcinoma: will BAT fly? Int J Radiat Oncol Biol Phys 1998;42: 215.
15. Pollack A, Zagars G, Starkshall G et al. Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996;34:555-564.
16. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43: 1095-1101.
17. Duchesne GM, Peters LJ. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 1999;44:747-748.
18. Harnisch G, Lalonde R, Weinhous M et al. Clinical usability of the BAT transabdominal ultrasound system for localization of the prostate: preliminary results. Med Phys 1998;25:A204.